Quantiaitive assessment of biomarker imaging for early threapeutic response to chemoradiotherapy

生物标志物成像对放化疗早期治疗反应的定量评估

• 批准号: 23591801
• 负责人: MATOBA Munetaka
• 金额: $ 2.33万
• 依托单位: Kanazawa Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591801/
• 关键词: 頭頸部癌; 化学放射線療法; 治療効果; MRI; PET-CT; 拡散強調画像; 予後予測; SUVmax; PET; 頭頚部癌; 治療効果判定; biomarker; diffusion MRI; PET/CT

The efficacy of apparent diffusion coefficient (ADC) of diffusion weighted MRI and standardized uptake value (SUV) of FDG PET-CT for prediction and early detection of treatment response and patient outcome to chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC) was investigated.The fractional changes in ADC between pre-treatment and during 3 weeks of treatment showed significant correlation with treatment response and patient outcome. In addition, the changes in SUVmax between pre-treatment and after 8weeks of treatment showed significant correlation with patinet outcome. The results suggest that the fractional changes in ADC and the changes in SUVmax are valid imaging biomarker for predicting treatment response and patinet outcome in HNSCC treated with chemoradiotherapy.

扩散加权MRI的明显扩散系数（ADC）以及FDG PET-CT的标准化吸收值（SUV）的预测和早期检测治疗反应和患者对化学疗法对头颈鳞状细胞癌（HNSCC）的治疗结果（HNSCC）（HNSCC）（HNSCC）的疗效。 结果。此外，在治疗和8周后，SUVMAX的变化与Patinet结果显着相关。结果表明，ADC的分数变化和SUVMAX的变化是预测用化学放疗治疗的HNSCC中治疗反应和PATINET结果的有效成像生物标志物。